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and Microvascular Endothelia Caused by Soluble
Factors Released to Blood by Autologous
Hematopoietic Stem Cell Transplantation
Marta Palomo,1 Maribel Diaz-Ricart,1 Montserrat Rovira,2 Gines Escolar,1 Enric Carreras2Endothelial activation and damage occur in association with autologous hematopoietic stem cell transplan-
tation (HSCT). Several of the early complications associated with HSCT seem to have a microvascular loca-
tion. Through the present study, we have characterized the activation and damage of endothelial cells of both
macro (HUVEC) and microvascular (HMEC) origin, occurring early after autologous HSCT, and the potential
protective effect of defibrotide (DF). Sera samples from patients were collected before conditioning (Pre), at
the time of transplantation (day 0), and at days 7, 14, and 21 after autologous HSCT. Changes in the expres-
sion of endothelial cell receptors at the surface, presence and reactivity of extracellular adhesive proteins,
and the signaling pathways involved were analyzed. The expression of ICAM-1 at the cell surface increased
progressively in both HUVEC and HMEC. However, a more prothrombotic profile was denoted for HMEC,
in particular at the time of transplantation (day 0), reflecting the deleterious effect of the conditioning treat-
ment on the endothelium, especially at a microvascular location. Interestingly, this observation correlated
with a higher increase in the expression of both tissue factor and vonWillebrand factor on the extracellular
matrix, together with activation of intracellular p38 MAPK and Akt. Previous exposure and continuous
incubation of cells with DF prevented the signs of activation and damage induced by the autologous sera.
These observations corroborate that conditioning treatment in autologousHSCT induces a proinflammatory
and a prothrombotic phenotype, especially at a microvascular location, and indicate that DF has protective
antiinflammatory and antithrombotic effects in this setting.
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Hematopoietic stem cell transplantation (HSCT)
is a well-established approach for the treatment of sev-
eral hematologicmalignancies andother nonmalignant
disorders [1]. Our group has demonstrated that endo-
thelial damage and activation occur not only associated
with allogeneic but also with autologous HSCT [2,3].1Hemotherapy-Hemostasis Department, Centre de Diag-
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6/j.bbmt.2010.11.019Theendothelium is an activebiological interface be-
tween the blood and all other tissues,whichmediates the
vasomotor tone, the hemostatic balance, and inflamma-
tory reactions, among other functions, throughout the
circulatory system [4]. Endothelial cell activation seems
to be a common pathogenic mechanism that may occur
locally or systemically [5]. Activation of the endothelium
takes place in a gradedmanner rather than in an ‘‘all-or-
nothing’’ response, and this reaction differs according to
several physiological variables including the location of
the vascular bed [5,6].
Using a macrovascular cell model, our group
reported endothelial damage associated with both the
allogeneic and the autologous HSCT, characterized
by an increase in the expression of adhesion receptors
on the cell surface, with leukocyte adhesion when cells
were exposed to circulating blood, and activation
of the p38 mitogen-activated protein kinase (p38
MAPK). In addition, a prothrombotic effect was also
observed, although only in the allogeneic setting, be-
cause of an enrichment of the extracellular matrix
(ECM) with vonWillebrand factor (VWF), correlated497
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to blood under flow conditions. Both the allo and the
auto settings induced cell proliferation, as measured
by activation of ERK42/44, although apoptosis, ap-
proached by measuring activation of the SAPK/JNK
pathway, was only observed in the group of allogeneic
HSCT recipients [2].
In the context of the HSCT, some of the early
complications associated, such as veno-occlusive dis-
ease (VOD), thrombotic microangiopathy, engraft-
ment syndrome, and capillary leak syndrome, among
others, are bound to the microvasculature injury [7].
Therefore, despite our previous observations in the
macrovascular cell model, effects on a microvascular
model should be explored, especially considering that
there are physiological differences among both cell
types [6,8], and that some studies have been only
performed in the allogeneic setting [9,10].
Defibrotide (DF) is a mixture of oligonucleotides
derived from the controlled depolymerization of por-
cine intestinal mucosal DNA [11,12]. There is strong
evidence demonstrating that DF is effective in the
treatment of VOD [7,13,14]. Although the mechanism
of action is uncertain, DF modifies the plasma levels of
a number of proteins involved in coagulation [15-18]
and reduces platelet and neutrophil functions [19].
Taken all these together, the aim of the present
study was to deepen into the endothelial activation
and damage associated with the autologous HSCT.
We have comparatively studied the proinflammatory
and prothrombotic phenotypes induced by the autolo-
gous HSCT environment in both the macro- and the
microvascular locations, by using the corresponding
cell models. The potential protective effect of DF on
both situations has also been explored.MATERIALS AND METHODS
Experimental Design
Human umbilical vein endothelial cells (HUVEC),
and an immortalized human microvascular endothelial
cell line-1 (HMEC-1), were used as macro- andmicro-
vascular cell models, respectively. Cells were grown in
the presence of 20% pooled sera collected at different
time points from patients under autologous HSCT.
We assessed changes in (1) the expression of the inter-
cellular adhesion molecule-1 (ICAM-1) at the cell sur-
face, (2) the thrombogenicity of the ECMgenerated by
these cells, (3) the expression of adhesion proteins such
as VWF and tissue factor (TF) on the ECM, and (4) al-
terations in the intracellular signal transduction
through phosphorylation of proteins, specifically p38
mitogen-activated protein kinase (p38 MAPK) and
Akt as key signalling factors critical in inflammation.
To explore the effect of DF, cells were incubated
with DF (100 mg/mL diluted in saline solution) for24 hours before being exposed to the sera under study,
and fresh doses of the drug were added every 24 hours.
To evaluate the effect of the transplant per se, the
results obtained with the sera samples from all the
time points along the transplant were compared with
those obtained with sera at day Pre (before the condi-
tioning treatment).The values obtained in the presence
ofDFwere statistically confrontedwith those obtained
in absence if this drug. Control experiments were per-
formed in parallel exposing cells to a 20% pool of sera
from healthy donors.
Patients
Patients receiving BEAM conditioning and autolo-
gous HSCT in our institution from January 2007 to
January 2009 were included in the study. Patients pre-
senting sepsis during the study period were excluded.
The group included 11 patients (5 females, 6 males),
median age 44 years (range: 29-72) suffering from
non-Hodgkin lymphoma (NHL) (6 cases), Hodgkin
disease (4 case), and chronic lymphocytic leukemia
(CLL) (1 case). All of them were treated with BEAM
regimen (carmustine 300 mg/m2 on day 27; etoposide
200 mg/m2 on days26,25,24,23; cytosine arabino-
side 200mg/m2ondays26,25,24,23; andmelphalan
140 mg/m2 on day 22). The engraftment (more than
0.5 109/L neutrophils) in these patients occurred after
11.3 6 1.5 days (mean 6 SEM). None of the patients
received any drug to prevent development of VOD.
Informed consent was obtained from all patients.
The study was approved by the ethical committee of
the Hospital Clinic and was carried out according to
the principles of the Declaration of Helsinki.
Sample Collection
Blood samples of the different patients were ob-
tained at different time points of the study: Pre (before
the conditioning regimen), day 0 (immediately before
the infusion of the hematopoietic progenitors), and
days 7, 14, and 21 after the HSCT. Blood samples
were always obtained through a central line to avoid
sample contamination with EC, and collected in BD
Vacutainer (#366468; BD Vacutainer Systems, Ply-
mouth, UK) tubs. Sera samples were obtained by cen-
trifugation of blood at 3000  g for 15 minutes and
immediately stored at 220C until used, and a pool
of sera at the different time points was prepared.
Human Endothelial Cell Culture
HUVEC were isolated from human umbilical
veins as previously described [20]. Cells were main-
tained and subcultured at 37C in a 5% CO2 humidi-
fied incubator in Medium 199 (Gibco BRL, Life
Technologies, Scotland, UK) supplemented with 100
U/mL penicillin, 100 g/mL streptomycin (Gibco
BRL, Life Technologies, Paisley, UK), and 20%
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[2,21]. Culture medium was replaced every 2 days.
Cells were used at a second passage cultured on 1%
gelatin-coated glass coverslips (18  18 mm2).
The human dermal microvascular endothelial cell
line CDC/EU.-HMEC-1 (further referred to as
HMEC) [22] was grown at 37C in a 5% CO2 humidi-
fied incubator inMDCB131medium (Gibco BRL, Life
Technologies) supplemented with 4% of L-glutamin,
1% of penicillin/streptomycin (Gibco BRL, Life Tech-
nologies), 1 mL/mL of hydrocortisone (Sigma-Aldrich
Quimica SA, Madrid, Spain), 10 ng/mL of Epidermal
Growth Factor (BD Biosciences, Erembodegem, Bel-
gium), and 10% fetal bovine serum (FBS) (Gibco
BRL,LifeTechnologies).Culturemediumwas replaced
every 2 days. Between the 10th and the 15th passage,
cellswere culturedon1%gelatin-coatedglass coverslips
(18  18 mm2).
HUVEC and HMEC cultures were divided into 2
fractions that were grown with media containing 20%
pooled sera from the autologous HSCT recipients at
the different time points under study, in the absence
or presence of fresh DF added every 24 hours. The
DF concentration was derived from the dose used in
vivo for therapy [7] and after revision of the bibliogra-
phy for the in vitro studies [19,23]. For the control
studies, cells were exposed to media containing 20%
pooled sera from healthy donors.Immunogold Labeling and Silver Enhancement
Glass coverslips coated with (1) endothelial cells
(EC) incubated with the sera pool during 2 days, and
(2) ECM from cells incubated with the samemedia dur-
ing 7 days,werefixedwith 4%paraformaldehyde in 0.15
M phosphate-buffered saline (PBS), pH 7.4 (4C, 10
min). The proteins evaluated were ICAM-1 on the cell
surface, andVWFandTFon theECM.Fixed coverslips
were incubated with monoclonal antibodies against
ICAM-1 (clone P2A4, Chemicon International, Teme-
cula, CA) (dilution 1/100), VWF (#A0082, Dako, Den-
mark) (dilution 1/1000), and TF (#4509, American
Diagnostica Inc., Greenwhih, CT) (dilution 1/100), or
an unspecific IgG, during 45 minutes at room tempera-
ture (RT) (n5 6). After removing the excess of antibody
by washing (3) with PBS, coverslips were incubated
with a gold-conjugated goat antimouse IgG (Amersham
Pharmacia Biotech, Essex, UK) (dilution 1/1000, 1
hour, RT). Finally, samples were treated with an intense
silver enhancement reagent (AmershamPharmacia Bio-
tech) to visualize gold particles bound to the antigen
[24,25]. The density of gold particles bound was
morphometrically analyzed using a light microscope
(Polyvar, Reichert-Jung, Reichert, Seefeld, Germany)
equipped with epi-polarizing filters (original magnifica-
tion320 for allmicrographs). Imageswere capturedby
a video camera (ProgResMF, Jena,Germany) and trans-ferred to a personal computer to evaluate, with an auto-
mated image analysis system (SigmaScan, Jandel
Scientific Software, Jandel GmbH, Erkrath, Germany),
the density of gold-particles on EC and ECM, which
was expressed as pixels/mm2.
Perfusion Studies
Composition and reactivity of the ECM generated
by macro- and microvascular cells were both evaluated.
EC monolayers grown on glass coverslips for 7 days
were extracted by treatment with 3% EGTA (1 hour
at 37C) to expose theECMon the coverslips. Perfusion
studies were carried out using a parallel-plate perfusion
chamber (at 800 s21 for 5 minutes) [26-28], exposing
ECM-coated coverslips to whole blood from a healthy
donor anticoagulated with citrate (at a final citrate con-
centration of 19 mM). After perfusion, coverslips were
rinsedwith 0.15MPBS, fixedwith 0.5%glutaraldehyde
in 0.15 M PBS at 4C for 24 hours, and stained with
0.02% toluidine blue. The degree of platelet deposition
wasmeasured in 10microscopic fields per coverslip, and
evaluated en facebymeansof anautomatedmethod [26].
The surface covered by platelets was expressed as a per-
centage with respect to the total area of the coverslip
screened (%SC).
To assess the involvement of the newly expressed
protein levels in the thrombogenicity of the ECM,
adhesion studies were performed in the presence of spe-
cific antibodies. ECM from HMEC grown with serum
from day 0 were incubated with antibodies to VWF
(Dako, Denmark) (dilution 1/1000) or TF (American
Diagnostica Inc.) (dilution 1/100), or unspecific IgG,
during 45 minutes at RT (n 5 6). After removing
the excess of antibody bywashing (3) with PBS, cover-
slips were perfused with citrated blood under flow
conditions.
Evaluation of Phosphorylation Kinetics of p38
MAPK and Akt
The effect of patients sera and the treatment with
DFonp38MAPK, andAktwas evaluated in cells starved
24 hours before experiments. Before and after being
exposed to sera pool (for 1 to 30 minutes), ECs were
lysed with Laemmli’s buffer (68.5 mM Tris (tris
[hydroxymethyl]aminomethane)-HCl), 2% SDS, 10%
glycerol, 5 mM b-mercaptoethanol, and 0.003%
bromophenol blue) containing 2 mM sodium ortho-
vanadate and 0.625mg/mLN-ethylmaleimide, as inhib-
itors. Samples were resolved by 8% SDS-PAGE and
transferred onto nitrocellulose membranes (BioRad,
Hercules, CA), which were probed with specific anti-
bodies to phosphorylated proteins: p38 MAPK, and
Akt (Cell Signaling Technology Inc., Danvers, MA)
[29,30]. The equal presence of protein in all the
samples evaluated was confirmed using BCA and using
specific antibodies.
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Results are expressed as mean 6 standard error of
the mean (SEM). Statistical analysis was performed
with raw data using the Student’s t-test for paired
samples and ANOVA. Results were considered statis-
tically significant when P\ .05. The SPSS statistical
package 17.0.0 (SPSS Inc, Chicago, IL) was used for
all analyses.RESULTS
The Increased Expression of ICAM-1 on
Endothelial Cells Induced by Sera from Patients
Undergoing Autologous HSCT Is Blocked by DF
An increased expression, especially at gap junctions,
of ICAM-1 was observed when both types of cells were
grown in the presence of sera from autologous HSCT
recipients. The increased expression of ICAM-1 was
significantly reduced because of the exposure to DF.
In HUVEC monolayers, ICAM-1 expression in-
creased significantly in a progressive manner along the
treatment to reach a peak of maximal expression at day
14 and decreasing at day 21 (filled bars, Figure 1A).
Values were of 45.9 6 8.3 pixels/mm2 at day 0, 60.3 6
14.5 pixels/mm2 at day 7, 105.8 6 31.5 pixels/mm2 at
day 14, and 66 6 21.4 pixels/mm2 at day 21 (P\ .05
from all values versus 21.4 6 6.7 pixels/mm2 at day
Pre, n 5 6). Preincubation and treatment of HUVECFigure 1. Expression of ICAM-1 on endothelial cells induced by autologous
HMEC exposed to sera from autologous HSCTrecipients, corresponding to d
fibrotide (HMEC 1 DF). Bar diagrams represent levels of ICAM-1 expression
ICAM-1 (pixels/mm2) in response to the sera from autologous recipients along
to the same conditions but in the presence of defibrotide. Dotted line represen
n 5 6, being *P\.05 versus day Pre, #P\.05 in the presence versus the absemonolayers with DF resulted in a significant reduction
on the expression of ICAM-1 caused by the pool of
sera under study (26.36 3.2 pixels/mm2 at day 0, 27.56
4.6 at day 7, 62.26 15.9 at day 14, and 54.66 23.6 at day
21, P\ .05 for all values versus those obtained without
DF, n5 6) (open bars, Figure 1A). Despite the obvious
inhibitory effect of DF, ICAM-1 surface expression
followed the same kinetics as the observed in cells non-
treated with this drug, being at day 14 significantly
higher than at day Pre (62.2 6 15.9 pixels/mm2 at
day 14 versus 9.9 6 4.7 pixels/mm2 at day Pre, n 5 6).
Control values were of 13.86 5.6 pixels/mm2.
InHMEC-1monolayers, ICAM-1 expression kinet-
ics were almost identical to that observed for the HU-
VEC cells. It increased significantly in a progressive
manner along the treatment to day 14, decreasing at
day 21 (filled bars, Figure 1B). Values were of 45.2 6 3
pixels/mm2 at day 0, 50.4 6 5 pixels/mm2 at day 7,
66.2 6 9 pixels/mm2 at day 14 (upper micrograph in
Figure 1), and 37.8 6 4 pixels/mm2 at day 21 (P\ .05
for all values versus 32.9 6 4 pixels/mm2 at day Pre,
n 5 6). Exposure to DF blocked the increase in
ICAM-1 (open bars, Figure 1B). All values were signifi-
cantly lower than those observed in cells not treatedwith
DF (26.2 6 6 pixels/mm2 at day 0, 29.2 6 7.3 at day 7,
23.26 5.3 at day 14, and 21.76 7 at day 21, P\ .05 ver-
sus for all values versus those obtained in cells not treated
withDF, n5 6) (lowermicrograph in Figure 1).Control
values were of 16.16 7.7 pixels/mm2.HSCT: effect of defibrotide. Micrographs show ICAM-1 expression on
ay 14, in the absence (HMEC) and in the presence of 100 mg/mL of de-
on HUVEC (A) and on HMEC (B). Filled bars correspond to levels of
the period of study in the absence of defibrotide. Open bars correspond
ts the mean value for control results. Data are expressed as mean6 SEM,
nce of defibrotide.
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Macrovascular and Microvascular ECs Grown in
the Presence of Sera from Patients Undergoing
Autologous HSCT: Changes in the Composition
and Preventive Effect of Defibrotide
When perfusing ECM from HUVEC grown with
culturemedium supplementedwith sera from the autol-
ogous HSCT recipients, a statistically significant in-
crease in the %SC by platelets was detected only at
day 14 (%SC of 27.8 6 2.3% versus %SC of 20 6
1.9% at day Pre, n 5 6, P \ .05) (filled bars,
Figure 2A). Previous exposure and treatment of cells
with DF caused a decrease in the thrombogenicity
caused by the sera from day 14 to control values (%SC
of 17.3 6 1.7% versus 27.8 6 2.3%, P\ .05, n 5 6)
(open bars, Figure 2A).
The growth of HMEC monolayers in the presence
of sera from the autologous HSCT recipients induced
a %SC by platelets of 27% 6 2.8%, 36.3% 6 1.7%,
28% 6 3%, 32.7% 6 3.7%, and 25.7% 6 3%, at days
Pre, 0, 7, 14, and 21, respectively (filled bars,
Figure 2B). Values were statistically significant at days
0 and 14 (P\ .05 for both versus day Pre, n5 6) (filled
bars, Figure 2B), being the sera from day 0 the most
prothrombotic (upper micrograph in Figure 2). Prein-
cubation and treatment of HMEC monolayers with
DF caused a reduction in the thrombogenicity of
the ECM generated by the sera under study (lowerFigure 2. Reactivity of the extracellular matrices from macrovascular and mic
sera: effect of defibrotide. Micrographs show platelet adhesion and aggregate
taining sera from autologous recipients, at day 0, in the absence (HMEC) and in
represent percentages of surface covered by platelets (%SC) on ECM fromHUV
sera from autologous recipients along the period of study in the absence of defi
ence of defibrotide. Dotted line represents the mean value for control results. D
#P\.05 in the presence versus the absence of defibrotide.micrograph in Figure 2) (22.6% 6 2.4% and 22.3% 6
3.6% at days 0 and 14, respectively; P\ .05 versus those
results on ECM not treated with DF). The values ob-
tained in the presence of DF were slightly lower than
the control values obtained in HUVEC and HMEC
(%SC of 18.06 2.0% and 25.6%6 3.0%, respectively)
(doted lines, Figure 2A-B), although differences never
reached statistical significance.
ECs Exposed to Sera from Autologous HSCT
Recipients Generate an ECM Enriched with
VWF and TF, Effect Prevented by DF
On HUVEC ECM, sera under study induced an
increase in the expression of VWF that reached statis-
tical significance only at day 14 with respect to day Pre
(89.5 6 15 versus 42 6 7 pixels/mm2, n 5 6, P\ .05).
At this time point, previous exposure and treatment of
HUVEC with DF caused a reduction in VWF expres-
sion to 67.8 6 17.5 pixels/mm2. No changes were
observed for TF.
On HMEC ECM, increases in VWF were also
observed when cells were grown in the presence of se-
rum samples from autologous HSCT recipients (filled
bars; Figure 3A). In comparison to day Pre (41.26 6.3
pixels/mm2), presence of VWF was statistically higher
at day 0 (63.16 5.3 pixels/mm2, P\ .05, n5 6) (micro-
graph labeled as VWF, Figure 3), and at day 14 (58.66
6 pixels/mm2, P\ .05, n 5 6). Previous exposure androvascular endothelial cells grown in the presence of autologous HSCT
formation on ECM generated by HMEC grown with culture media con-
the presence of 100 mg/mL of defibrotide (HMEC1 DF). Bar diagrams
EC (A) and HMEC (B). Filled bars correspond to %SC in response to the
brotide. Open bars correspond to the same conditions but in the pres-
ata are expressed as mean6 SEM, n5 6, being *P\.05 versus day Pre,
502 Biol Blood Marrow Transplant 17:497-506, 2011M. Palomo et al.treatment of HMEC with DF prevented the increases
in VWF and maintained the levels of expression at
control ranges (47.1 6 7.5 pixels/mm2) (open bars,
Figure 3A) (see micrograph labeled as VWF 1 DF).
Interestingly, the sera from patients undergoing
autologous HSCT also induced the expression of TF
on HMEC ECM (filled bars, Figure 3B), being statisti-
cally significant at days 0 and 14 (61 6 8.9 pixels/mm2
and 45.56 6.6 pixels/mm2, respectively, P\ .05 versus
23.46 1.2 pixels/mm2 at day Pre, n5 6) (seeTF expres-
sion at day 0 on micrograph labeled as TF; Figure 3).
This effect was blocked when cells were preincubated
and treated with DF (24.16 3.3 and 26.16 3.1 pixels/
mm2 at days 0 and 14, respectively, P \ .05, n 5 6)
(open bars; Figure 3B) (see micrograph labeled as TF1
DF). Control values were of 186 3.1 pixels/mm2.
The surface covered by platelets decreased in the
presence of both the anti-VWF and the anti-TF anti-
bodies from 37.2% 6 2.1%, to 22.2% 6 0.6% andFigure 3. Expression of VWF and tissue factor on the extracellular matrix fro
Micrographs show VWF and TF expression on the ECM from HMEC exposed
absence (upper micrographs VWF and TF) and in the presence of 100 mg/mL of
represent levels of VWF (A) and TF (B) expression on ECM from HMEC. Filled
sera from autologous recipients along the period of study in the absence of
presence of defibrotide. Dotted line represents the mean value for control re
day Pre, #P\.05 in the presence versus the absence of defibrotide.28.1% 6 1.9%, respectively (P \ .05, n 5 6)
(Figure 4). No differences were observed when com-
paring these values with that obtained in the presence
of DF (25.6% 6 3.1%, n 5 6).Presence of Sera from Autologous HSCT
Recipients Induces Activation of p38 and Akt in
ECs, Which Is Prevented by DF
In the HUVEC setting, protein p38MAPK be-
came intensely activated in response to sera from au-
tologous recipients at both days 0 and 14, and lasted
for at least 30 minutes (Figure 5A). At both days
0 and 14, the prophylactic treatment of cells with DF
inhibited the phosphorylation of this inflammatory
signaling pathway (Figure 5A). No significant changes
were observed in control samples (Figure 5A). The
activation of p38MAPK in the HMEC setting fol-
lowed similar kinetics to those observed in HUVECm HMEC cells exposed to autologous HSCT sera: effect of defibrotide.
to sera from autologous HSCTrecipients, corresponding to day 0, in the
defibrotide (lower micrographs VWF1DF and TF1DF). Bar diagrams
bars correspond to levels of VWF or TF, respectively, in response to the
defibrotide. Open bars correspond to the same conditions but in the
sults. Data are expressed as mean 6 SEM, n 5 6, being *P\.05 versus
Figure 4. Reactivity of the extracellular matrices from microvascular
endothelial cells grown in the presence of autologous HSCT sera: effect
of defibrotide. Micrographs show platelet adhesion and aggregate for-
mation on ECM generated by HMEC grown with culture media contain-
ing sera from autologous recipients, at day 0, in the absence (HMEC) and
in the presence of antibodies to VWF (HMEC 1 anti-VWF) and to TF
(HMEC 1 anti-TF).
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intensity.
Although only mildly, the activation of Akt was al-
ready detected under starving conditions in both HU-
VEC andHMEC, even in cells exposed to control sera.
However, the exposure of both cell types to patients
sera from day 0 and 14 increased notably the phos-
phorylation of Akt (Figure 5A and B). The presence
of DF clearly decreased the activation of Akt in both
HUVEC and HMEC cells (Figure 5A and B).DISCUSSION
Our previous studies demonstrated that there is re-
lease of soluble factors after HSCT to the circulation
that contribute to the activation and damage of macro-
vascular EC. This fact is not limited to the allogeneic
setting but also occurs in the autologous HSCT [2,3].
There is evidence that some of the early complications
associated with HSCT occur in a microvascular
location [31]. Through the present study we have
explored the activation and damage of EC of both
macro- (HUVEC) and microvascular (HMEC) origin
occurring early during autologous HSCT, and the
potential protective effect of defibrotide. Our results
indicate that there is activation and damage of EC in
both types of cells with similar signs of inflammation,
althoughwith amore reactiveECMin cells ofmicrovas-
cular origin. Interestingly,DFshowedaprotective effect
on both cell lines by preventing the development of the
proinflammatory and prothrombotic phenotypes.
Activation of endothelial cells is a common
pathogenetic mechanism in vascular occlusions, and
can be induced by a wide range of agents [6,8].
Changes in activated EC include loss of the vascular
integrity, expression of adhesion molecules, cytokine
production, and changes from an antithrombotic to
a prothrombotic phenotype [5]. Although some differ-
ences between microvascular endothelial cells and
large-vessel EC have been described, it is assumed
that both types of cells are basically comparable [32].
Nevertheless, because most of the clinically detectable
complications appearing early after HSCT have a mi-
crovascular location, we have comparatively evaluated
the potential differences in the response of the 2 vascu-
lar bed cells to the stimuli induced by those factors
released during HSCT to the patients’ sera, and the
effect of DF on both cell types.
In the present study, with classical BEAM condi-
tioning (etoposide 800 mg/m2), we were able to repro-
duce the findings obtained in our previous studies [2],
in which BEAM conditioning included a higher dose
of etoposide (1600mg/m2). Although the proinflamma-
tory reaction of the macrovascular endothelial cells to
BEAM 800 was less intense than with BEAM 1600,
endothelial activation and damage followed the same ki-
netics, with a progressive increase of ICAM-1 receptors
from day Pre to day 14. The results described in the
previous and present studies are probably because of
the integrated effect of the conditioning regimen, ad-
ministration of granulocyte-colony stimulating factor
(G-CSF), the translocation of endotoxins, and the en-
graftment process [2,3]. Microvascular ECs showed to
be less reactive to the inflammatory stimuli caused by
the sera from autologous HSCT recipients as derived
from the lower levels of expression of ICAM-1 at the
cell surface, although they exhibited similar kinetics.
Interestingly, the increase in the expression of adhesion
Figure 5. Activation of the signaling molecules p38 MAPK and Akt in HUVEC and HMEC by autologous HSCT sera: effect of defibrotide. Activation of
p38 MAPK and Akt was measured in HUVEC and HMEC cells in presence or absence of 100 mg/mL of DF during the previous 24 hours, and activated
with the sera samples from autologous recipients collected at days 0 and 14. Exposure was carried out for 15 and 30 minutes to assess the kinetics of
activation. Images are representative of n 5 6 different experiments.
504 Biol Blood Marrow Transplant 17:497-506, 2011M. Palomo et al.receptors at the cell surface in both cells occurs in paral-
lel with the activation of both p38MAPK and Akt, both
being signaling proteins associated with inflammation
and stress responses [33,34]. Although the presence of
proinflammatory cytokines, such as interleukin (IL)-1,
tumor necrosis factor (TNF)-a, and interferon gamma
(INF-g), in the blood of HSCT recipients has been
reported [35], the specific nature of those involved in
the development of the endothelial dysfunction should
be further investigated.
There are few reports on the functional heteroge-
nicity of EC derived from different origins. The differ-
ential characteristics between HUVEC and HMEC
have been ascribed to both a genetic predisposition
and environmental influences [4,8], which determine
the type and number of cell adhesion molecules
expressed [22], and the macromolecular composition
of the ECM [36], among others. In this regard, it has
been reported by Ribeiro et al. [37] that HMEC do
not synthesize VWF at the same levels as HUVEC,
being poorly present in ECM generated by microvas-
cular cells [36].
From our results, the ECM generated by macro-
vascular cells appeared to be mainly proadhesive, as
derived from the patterns of platelet adhesion with
small-sized aggregates and many single platelets in
contact. In our setting, the reactivity of the macrovas-
cular ECM only increased significantly when cells
were exposed to sera from day 14. In contrast, platelet
adhesion onto microvascular ECM consisted of largeaggregates, and it increased really significantly when
cells were exposed to the sera from patients undergo-
ing autologous HSCT at the time of transplant (day
0). These results paralleled with a higher expression
of VWF on both cell types ECM. Moreover, it is
interesting to point out that TF was also significantly
expressed, but only in the microvascular ECM, espe-
cially at the day of transplantation. Because TF is
a major activator of the extrinsic pathway of blood
coagulation, the synthesis and release of this protein
to the ECM may have important thrombotic conse-
quences at the microvascular location.
Through the present study, the prophylactic effect
of DF on the alterations of endothelial cell function
induced by the autologous HSCT was explored in
both locations. Defibrotide inhibited not only the in-
flammatory reaction, by avoiding the expression of
adhesion receptors at the cell surface, but also the
thrombogenic phenotype, by preventing the changes
in the ECM composition generated by the serum com-
ponents in both macro- and microvascular EC. There
are many publications describing the beneficial effects
of defibrotide as profibrinolytic, antithrombotic, and
thrombolytic, antischemic, antishock, antiatheroscler-
otic, and antirejection drug [38]. However, the precise
molecularmechanisms are still a subject of investigation.
Through thepresent study,wepropose a potential effect
of DF on the signaling pathways involving p38MAPK
and Akt, which become activated by stress situations
[33,39]. Downstream from these signaling cascades
Biol Blood Marrow Transplant 17:497-506, 2011 505Defibrotide Prevents Endothelial Activationthere is activation of transcription factors that regulate
the synthesis of proteins. The proinflammatory and
prothrombotic effects on the endothelial cells
described in the HSCT setting occur with the
synthesis and release of adhesion receptors and
adhesive proteins, and these effects are interferedbyDF.
In theHSCTsetting,DF is awell-tolerated drug that
is successfully used for the treatment [7,11,13] and
prophylaxis (Corbacioglu et al., oral comunication in
EBMT meeting 2010) of VOD, 1 of the major hepatic
complications of HSCT. The effect of DF has been
mainly explored in the allogeneic HSCT [10]. The pres-
ent study provides the first evidence that the prophylactic
exposure and treatment of cells with DF results in a pro-
tective antiinflammatory and antithrombotic effect in an
in vitro model of endothelial dysfunction associated
with autologous HSCT. Although there are several
reports on the beneficial effects of defibrotide on hemo-
stasis [12,19], there is no previous evidence describing
the direct effect of DF on the release of VWF and TF
to the extracellular matrix from both macro- and
microvascular locations. This effect may be of clinical
significance to be considered as a preventive treatment
for those complications appearing early in association
with HSCT.
Our study demonstrates that those factors present
in the sera of autologous recipients cause the activation
and damage on endothelial cells, showing a more
proinflammatory phenotype in macrovascular endo-
thelial cells and a more prothrombotic effect on cells
of microvascular origin. These results could explain
that most of the complications that appear early in as-
sociation with HSCT have a microvascular location.
Interestingly, our present results are the first evidence
demonstrating that DF has a protective antiinflamma-
tory and antithrombotic effect associated with autolo-
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